4//SEC Filing
Mika Yuval 4
Accession 0001213900-23-006198
CIK 0001814114other
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 9:36 PM ET
Size
13.1 KB
Accession
0001213900-23-006198
Insider Transaction Report
Form 4
Mika Yuval
See Remarks
Transactions
- Award
Incentive Stock Option (Right to Buy)
2023-01-26+46,500→ 46,500 totalExercise: $4.30From: 2023-01-26Exp: 2028-08-07→ Common Stock (46,500 underlying) - Award
Nonstatutory Stock Option (Right to Buy)
2023-01-26+69,870→ 69,870 totalExercise: $4.30From: 2023-01-26Exp: 2028-08-07→ Common Stock (69,870 underlying) - Award
Nonstatutory Stock Option (Right to Buy)
2023-01-26+234,242→ 234,242 totalExercise: $10.00Exp: 2032-08-25→ Common Stock (234,242 underlying) - Award
Common Stock, par value $0.0001 per share ("Common Stock")
2023-01-26+40,720→ 40,720 total
Footnotes (6)
- [F1]These securities were issued on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for Legacy Orchestra securities.
- [F2]Received in the Business Combination in exchange for 87,571 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock").
- [F3]Received in the Business Combination in exchange for a nonstatutory stock option to acquire 150,259 shares of Legacy Orchestra Common Stock for $2.00 per share.
- [F4]The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares vested on the grant date and (ii) 67% of the underlying shares have vested and will vest in equal installments on a quarterly basis on the last day of each quarter, starting with the end of the first quarter after the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022.
- [F5]Received in the Business Combination in exchange for a nonstatutory stock option to acquire 503,746 shares of Legacy Orchestra Common Stock for $4.65 per share.
- [F6]Received in the Business Combination in exchange for an incentive stock option to acquire 100,000 shares of Legacy Orchestra Common Stock for $2.00 per share.
Documents
Issuer
Orchestra BioMed Holdings, Inc.
CIK 0001814114
Entity typeother
Related Parties
1- filerCIK 0001949285
Filing Metadata
- Form type
- 4
- Filed
- Jan 29, 7:00 PM ET
- Accepted
- Jan 30, 9:36 PM ET
- Size
- 13.1 KB